Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 21;3(4):121.
doi: 10.3390/tropicalmed3040121.

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

Miriam Tendler  1 , Marília S Almeida  2 , Monica M Vilar  3 , Patrícia M Pinto  4 , Gabriel Limaverde-Sousa  5
Affiliations
Review

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

Miriam Tendler et al. Trop Med Infect Dis. .

Erratum in

Abstract

Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequality, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although chemotherapy is capable of reducing morbidity in humans, rapid re-infection demonstrates that the impact of drug treatment on transmission control or disease elimination is marginal. In addition, despite more than two decades of well-executed control activities based on large-scale chemotherapy, the disease is expanding in many areas including Brazil. The development of the Sm14/GLA-SE schistosomiasis vaccine is an emblematic, open knowledge innovation that has successfully completed phase I and phase IIa clinical trials, with Phase II/III trials underway in the African continent, to be followed by further trials in Brazil. The discovery and experimental phases of the development of this vaccine gathered a robust collection of data that strongly supports the ongoing clinical phase. This paper reviews the development of the Sm14 vaccine, formulated with glucopyranosyl lipid A (GLA-SE), from the initial experimental developments to clinical trials including the current status of phase II studies.

Keywords: FABP; Sm14; schistosomiasis; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline: Sm14/GLA-SE anti-schistosomiasis vaccine - from discovery phase to final product. MAPA: Brazilian Ministry of Agriculture.
See this image and copyright information in PMC

References

    1. Chitsulo L., Engels D., Montresor A., Savioli L. The global status of schistosomiasis and its control. Acta Trop. 2000;77:41–51. doi: 10.1016/S0001-706X(00)00122-4. - DOI - PMC - PubMed
    1. Steinmann P., Keiser J., Bos R., Tanner M., Utzinger J. Schistosomiasis and water resources development: Systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis. 2006;6:411–425. doi: 10.1016/S1473-3099(06)70521-7. - DOI - PubMed
    1. Osakunor D.N.M., Woolhouse M.E.J., Mutapi F. Paediatric schistosomiasis: What we know and what we need to know. PLoS Negl. Trop. Dis. 2018;12:e0006144. doi: 10.1371/journal.pntd.0006144. - DOI - PMC - PubMed
    1. Poole H., Terlouw D.J., Naunje A., Mzembe K., Stanton M., Betson M., Lalloo D.G., Stothard J.R. Schistosomiasis in pre-school-age children and their mothers in Chikhwawa district, Malawi with notes on characterization of schistosomes and snails. Parasit. Vectors. 2014;7:153. doi: 10.1186/1756-3305-7-153. - DOI - PMC - PubMed
    1. Bergquist R., van Dam G.J., Xu J. Diagnostic tests for schistosomiasis. In: Jamieson B.G.M., editor. Schistosoma: Biology, Pathology and Control. 1st ed. CRC Press; Boca Raton, FL, USA: 2016. pp. 401–439.

LinkOut - more resources